false
OasisLMS
Login
Catalog
Addressing Barriers to Clozapine Underutilization
View Presentation
View Presentation
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
This webinar, presented by Dr. Deanna Kelly and Dr. Raymond Love and hosted by the American Psychiatric Association, addresses the significant underutilization of clozapine in treating treatment-resistant schizophrenia and other serious mental illnesses. Clozapine is recognized as the most effective antipsychotic for treatment-resistant schizophrenia, offering superior symptom reduction and cost savings compared to other antipsychotics. Despite evidence and guideline recommendations to use clozapine after two failed antipsychotic trials, its use remains low—below 5% in the U.S.—due to numerous barriers.<br /><br />Key barriers include mandatory regular blood monitoring, fear of serious side effects (like neutropenia and myocarditis), inadequate provider training, service fragmentation, and logistical challenges such as blood draw coordination and patient adherence. Particularly important is the issue of benign ethnic neutropenia (BEN), prevalent in African-American and some other ethnic populations, which complicates monitoring due to naturally lower neutrophil counts, contributing to lower clozapine use and higher discontinuation in these groups. New guidelines now allow adjusted monitoring for BEN patients.<br /><br />Efforts to overcome barriers include developing centralized resources, multidisciplinary clozapine clinics, improving education and training, enhancing REMS (Risk Evaluation and Mitigation Strategy) systems, and exploring innovative solutions like point-of-care finger stick blood testing devices to ease monitoring burdens. National workgroups recommend roles for various stakeholders, including prescribers, health systems, payers, and correctional facilities, to improve access and safe use of clozapine to benefit millions of patients.
Keywords
clozapine
treatment-resistant schizophrenia
antipsychotics
blood monitoring
benign ethnic neutropenia
side effects
provider training
REMS
multidisciplinary clinics
×
Please select your language
1
English